Search results
Showing 106 to 120 of 148 results for copd
This guideline has been updated and replaced by NICE guideline CG101.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)
This evidence summary has been updated and replaced by NICE guideline 115.
This evidence summary has been updated and replaced by NICE guideline 115.
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.
Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)
This evidence summary has been updated and replaced by NICE guideline 115.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)
We have moved interventional procedures guidance 714 to become HealthTech guidance 604. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)
This evidence summary has been updated and replaced by NICE guideline 115.
myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
This advice has been updated and replaced by NICE medical technologies guidance 68.
Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)
This guidance has been updated and replaced by NICE technology appraisal guidance 461.